In line with our findings, others reported that CD8+ T cells infiltrating BRAFV600E‐metastatic melanoma lesions in patients produced more effector cytokines when tumor cells were pretreated with BRAFi49; and higher levels of granzyme B in BRAFi‐responsive metastatic melanoma samples were observed.18 Moreover, in a preclinical mouse model, more IFN‐γ/TNF‐α double producing T cells were present in BRAFi‐treated tumors.20 Another well‐defined activating receptor is NKG2D, which is expressed on both NK and T cells. The gene discussed is KLRK1; the disease is metastatic melanoma.